STADA Arzneimittel Aktiengesellschaft (SAZ) Stock Price, News & Analysis

Company Overview

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

Key Stats

• Today's Range: €79.56 to €80.98
• 50-Day Range: €80.40 to €80.40
• 52-Week Range: €53.41 to €80.98
• Volume: 92,068 shs
• Average Volume: 51,761 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SAZ Stock Analysis - Frequently Asked Questions

How have SAZ shares performed this year?

STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 on January 1st, 2024. Since then, SAZ stock has increased by 0.0% and is now trading at €80.40.
View the best growth stocks for 2024 here.

What other stocks do shareholders of STADA Arzneimittel Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some other companies that STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Sarepta Therapeutics (SRPT), Volkswagen Aktiengesellschaft (VLKAY), Volkswagen (VOW3), ACADIA Pharmaceuticals (ACAD) and Adverum Biotechnologies (ADVM).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: ETR:SAZ
• CUSIP: N/A
• CIK: N/A
• Web: www.stada.de
• Phone: +49-6101-6030
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A